7.43
-0.01 (-0.13%)
| Previous Close | 7.44 |
| Open | 7.44 |
| Volume | 146,499 |
| Avg. Volume (3M) | 345,827 |
| Market Cap | 514,556,480 |
| Price / Sales | 17.73 |
| Price / Book | 0.660 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Operating Margin (TTM) | -703.66% |
| Diluted EPS (TTM) | -3.16 |
| Quarterly Revenue Growth (YOY) | -48.90% |
| Total Debt/Equity (MRQ) | 1.12% |
| Current Ratio (MRQ) | 14.86 |
| Operating Cash Flow (TTM) | -180.22 M |
| Levered Free Cash Flow (TTM) | -108.88 M |
| Return on Assets (TTM) | -21.69% |
| Return on Equity (TTM) | -37.07% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Bicycle Therapeutics plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | 0.63 |
|
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.46% |
| % Held by Institutions | 93.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Point72 Asset Management, L.P. | 31 Mar 2025 | 3,692,069 |
| Fcpm Iii Services B.V. | 31 Mar 2025 | 3,452,330 |
| Long Focus Capital Management, Llc | 31 Mar 2025 | 1,293,753 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 32.00 (RBC Capital, 330.69%) | Buy |
| Median | 19.50 (162.45%) | |
| Low | 14.00 (B. Riley Securities, 88.43%) | Hold |
| Average | 21.50 (189.37%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 8.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 06 May 2025 | 17.00 (128.80%) | Hold | 7.40 |
| B. Riley Securities | 02 May 2025 | 14.00 (88.43%) | Hold | 9.30 |
| JMP Securities | 02 May 2025 | 22.00 (196.10%) | Buy | 9.30 |
| Needham | 02 May 2025 | 29.00 (290.31%) | Buy | 9.30 |
| 09 Apr 2025 | 30.00 (303.77%) | Buy | 6.88 | |
| RBC Capital | 02 May 2025 | 32.00 (330.69%) | Buy | 9.30 |
| Barclays | 01 May 2025 | 15.00 (101.88%) | Buy | 9.08 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Jun 2025 | Announcement | Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 22 May 2025 | Announcement | Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting |
| 05 May 2025 | Announcement | Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 01 May 2025 | Announcement | Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results |
| 29 Apr 2025 | Announcement | Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |